Skip to content
Disclosery

GILEAD SCIENCES, INC.

Follow

13F filer, CIK 882095, FOSTER CITY, CA

GILEAD SCIENCES, INC. reported $2,117,784,504 across 6 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-26-000642

Period
2026-03-31
Reported value
$2.12B
Holdings
6
Top 10 weight
100%
New
0
Sold out
0

Part of the filer group GILEAD SCIENCES, INC.

How groups are built

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
XLOreduced-8,455,062-$71.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001123292-26-000642, largest first. % of portfolio is the value over $2,117,784,504, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 6,720,803 shares; 2025Q1: 6,720,803 shares; 2025Q2: 6,720,803 shares; 2025Q3: 6,720,803 shares; 2025Q4: 6,720,803 shares; 2026Q1: 6,720,803 shares 6,720,803$772M36.44%0Timeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 30,061,124 shares; 2025Q1: 31,424,760 shares; 2025Q2: 31,424,760 shares; 2025Q3: 31,424,760 shares; 2025Q4: 31,424,760 shares; 2026Q1: 31,424,760 shares 31,424,760$679M32.05%0Timeline
LKFTLAKEFRONT BIOTHERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 16,707,477 shares; 2025Q1: 16,707,477 shares; 2025Q2: 16,707,477 shares; 2025Q3: 16,707,477 shares; 2025Q4: 16,707,477 shares; 2026Q1: 16,707,477 shares 16,707,477$501M23.67%0Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,209,471 shares; 2025Q1: 2,209,471 shares; 2025Q2: 2,209,471 shares; 2025Q3: 4,505,391 shares; 2025Q4: 4,505,391 shares; 2026Q1: 4,505,391 shares 4,505,391$125M5.9%0Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 4,126,119 shares; 2025Q1: 4,126,119 shares; 2025Q2: 4,126,119 shares; 2025Q3: 4,126,119 shares; 2025Q4: 4,126,119 shares; 2026Q1: 4,126,119 shares 4,126,119$35.6M1.68%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 9,105,451 shares; 2025Q1: 9,105,451 shares; 2025Q2: 9,105,451 shares; 2025Q3: 9,105,451 shares; 2025Q4: 9,105,451 shares; 2026Q1: 650,389 shares 650,389$5.47M0.26%-8,455,062Timeline

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-26-000642 base2026-05-08acceptance time not in the bulk data set